There have been reports of noninfectious pneumonitis (including some with pulmonary hypertension as a secondary event), infections, and renal failure (including acute renal failure) in patients...
Give your patients the answers they need about metastatic HR+, HER2-negative breast cancer and treatment with AFINITOR.
Use this sheet as a quick reference when starting treatment with AFINITOR.
Information and resources for treatment with AFINITOR are available directly to patients. Click here to view the AFINITOR patient site and learn more about these helpful patient services.
AFINITOR is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole.
Important Safety Information
AFINITOR is contraindicated in patients with clinically significant hypersensitivity to everolimus or to other rapamycin derivatives.
Severe Hypersensitivity Reactions
Angioedema With Concomitant Use of Angiotensin-Converting Enzyme (ACE) Inhibitors
Impaired Wound Healing
Risk of Infection or Reduced Immune Response With Vaccinations
Please see full Prescribing Information.